Hepatitis C and human immunodeficiency virus infection

Area of Science:

• Hepatology
• Infectious Diseases
• Immunology

Background:

• Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection affects 200,000 individuals in the U.S.
• HIV treatment advances have prolonged survival, making liver disease a leading cause of mortality in coinfected patients.
• HIV exacerbates HCV progression and increases antiretroviral therapy-related liver toxicity.

Purpose of the Study:

• To review the impact of HIV on HCV infection and vice versa.
• To discuss the challenges and current controversies in managing HCV in HIV-coinfected individuals.
• To highlight the need for evidence-based management strategies.

Main Methods:

• Literature review and synthesis of existing data on HIV/HCV coinfection.
• Analysis of the interplay between HIV and HCV disease progression.
• Evaluation of treatment implications and toxicities.

Main Results:

• HIV infection accelerates HCV-related liver disease progression and increases viral persistence.
• HCV coinfection can increase the risk of liver toxicity from HIV antiretroviral medications.
• Current management strategies are based on data from non-HIV-infected populations and understanding of both diseases.

Conclusions:

• The significant burden of liver disease in coinfected individuals necessitates proactive management.
• Further research and clinical trials are crucial for optimizing HCV treatment in coinfected patients.
• Management should integrate knowledge of both infections, even with limited coinfection-specific data.